Abstract 186P
Background
Sorafenib is a multikinase inhibitor used to treat patients with unresectable hepatocellular carcinoma (HCC); however, there is no consensus on its efficacy in patients with HCC post hepatic resection. Therefore, this meta-analysis (PROSPERO ID: CRD42019122147) assessed efficacy and safety of sorafenib in patients with HCC who underwent hepatic resection.
Methods
Using PICO framework, relevant articles were retrieved from PubMed, EMBASE, Cochrane Library and Google Scholar. Articles comparing outcomes of sorafenib treated patients with HCC who underwent resection with those not receiving sorafenib were included for the analysis The primary outcome was overall survival (OS) while disease free survival (DFS), tumor recurrence rate (TRR), mortality and safety were the secondary outcomes. Hazard ratio (HR) or risk ratio (RR) along with 95% confidence interval (CI) were calculated by fixed or random effects (FE or RE) model, based on the heterogeneity. P < 0.05 was considered significant. The effect of portal vein tumor thrombosis (PVTT) and time of initiation of sorafenib therapy on survival were assessed by subgroup analysis.
Results
A total of 10 studies with data of 589 patients (mean age 52.41 years; men: 87.28%; women: 12.72%) were included in the analysis. Sorafenib significantly prolonged OS (n = 5; FE; HR: 0.69; 95% CI; 0.52, 0.93; P =.0139), reduced TRR (n = 8; FE; RR: 0.91; 95% CI: 0.83, 0.98; P =.0187) and mortality (n = 7; FE; RR: 0.75; 95% CI: 0.63, 0.88; P =.0007) in patients with HCC following hepatic resection compared to the control group. Further, DFS in the sorafenib group was non-significantly better than the control group (n = 5; FE; HR: 0.78; 95% CI: 0.56, 1.09; P =.1462). Although, the proportion of adverse events (AEs) was higher in the sorafenib group (81.1% vs 18.9%), the AEs were tolerable. Subgroup analysis revealed sorafenib to be more effective (lower TRR and mortality) in patients without PVTT than those with PVTT.
Conclusions
Adjuvant sorafenib treatment improved survival outcomes in HCC patients post hepatic resection and had acceptable safety profile. Hence, sorafenib could be recommended as an adjuvant therapy for patients with HCC after hepatic resection.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Science Fund for Creative Research Groups, NSFC, China (81521091); State key infection disease project of China (2018ZX10732202-002-005); National Human Genetic Resources Sharing Service Platform (2005DKA21300);.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
87P - Negative to positive lymph node ratio-prognostic marker of survival in node positive rectal cancer
Presenter: Pavan Jonnada
Session: Poster display session
Resources:
Abstract
88P - The Sidra LUMC advanced colon cancer NGS cohort
Presenter: Wouter Hendrickx
Session: Poster display session
Resources:
Abstract
89P - A phase II trial of adjuvant chemoradiotherapy for patients with high-risk rectal submucosal invasive cancer after local resection
Presenter: Masaaki Noguchi
Session: Poster display session
Resources:
Abstract
90P - High MICB expression confers prognostic benefit in colorectal cancer
Presenter: Shanchao Yu
Session: Poster display session
Resources:
Abstract
91P - Adjuvant therapy for high-risk stage II or stage III colon adenocarcinoma: A propensity score-matched, nationwide, population-based cohort study
Presenter: Chien-Hsin Chen
Session: Poster display session
Resources:
Abstract
92P - Prospective randomized controlled study comparing primary surgery versus neoadjuvant chemotherapy followed by surgery in gastric carcinoma
Presenter: Vipin Goel
Session: Poster display session
Resources:
Abstract
93P - Biomarker selection of liver metastatic colorectal patients for anti-EGFR monoclonal antibodies: A machine learning analysis
Presenter: Yijiao Chen
Session: Poster display session
Resources:
Abstract
94P - NORTH/HGCSG1003: North Japan multicenter phase II study of oxaliplatin-containing regimen as adjuvant chemotherapy for stage III colon cancer: Final analysis
Presenter: Michio Nakamura
Session: Poster display session
Resources:
Abstract
95P - Anatomical resections improve relapse-free survival in patients with KRAS/NRAS/BRAF- mutated colorectal liver metastases
Presenter: Ye Wei
Session: Poster display session
Resources:
Abstract
96P - Incidence, characteristics and prognosis in colorectal cancer with CNS metastases
Presenter: Nicola Taylor
Session: Poster display session
Resources:
Abstract